📰 Binding Domain News
Binding Domain News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Binding Domain. Real-time updates on events, politics, business and more.
October 24, 2023
A single-dose intranasal vaccine effectively induces robust immune responses.
October 9, 2023
Using antigenic cartography, researchers analyzed cross-reactivity patterns of SARS-CoV-2 variants and the effect of spike-protein changes on post-infection and vaccination immune responses. The study illuminated unique neutralization profiles and underscored the evolving defense mechanisms with repeated immunizations.
July 27, 2022
In a new study, investigators studied a linear deoxyribonucleic acid (linDNA) SARS-CoV-2 vaccine option in felines.
July 16, 2022
WHO is tracking highly-mutated COVID-19 sub-variant nicknamed Centaurus (BA.2.75)
May 29, 2022
News highlights on health security threats and countermeasures curated by Global Biodefense This week's selections include the surge in monkeypox cases
May 13, 2022
A team of scientists has recently studied the kinetic and thermodynamic characteristics of interaction between human ACE2 and spike receptor-binding domains of different variants of SARS-CoV-2.
January 28, 2022
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic due to the high transmission and mortality rate of this virus. The world health and economic sectors have been severely affected by this deadly virus, exacerbated by the lack of sufficient efficient vaccines. The design of effective drug candidates and their rapid development is necessary to combat this virus. In this study, we selected 23 antimicrobial peptides from the literature and predicted thei...
January 14, 2022
Researchers test the durability of antibodies produced by a vaccine-induced full-length SARS-CoV-2 spike protein and receptor-binding domain.
October 27, 2021
The heterologous ChAd/BNT combination confers better protection against SARS-CoV-2 infection than the homologous BNT/BNT combination in a real-world observational study of healthcare workers.
July 16, 2021
New vaccine candidate could be a cost-effective option against emerging SARS-CoV-2 variants A multidisciplinary team of researchers is the first to show combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which appl...